

## Special Issue

# Targeting the PI3K/AKT/mTOR Pathway in Cancer: Mechanisms and Advances in Clinical Trials

### Message from the Guest Editors

The PI3K/AKT/mTOR signaling pathway is critically important for the regulation of cell growth. Its disruption is seen in many cancer types as well as in a number of inherited syndromes. We are pleased to invite you to contribute to a Special Issue on “Targeting the PI3K/AKT/mTOR pathway in Cancer: Mechanisms and Advances in Clinical Trials”. Through this, we hope to highlight the progress the field has made at a molecular level and how this knowledge has been translated to provide new treatment options for the management of cancer patients. We also aim to clarify the gaps in knowledge and challenges that still remain to be addressed. In this Special Issue, both original research articles and reviews are welcome. Submissions can cover any relevant topic, including PI3K/AKT/mTOR signaling mechanisms, inputs, and feedback; dysregulation of PI3K/AKT/mTOR in cancer; progress in clinical trials; challenges for the field; the future of mTOR-targeted therapeutics. We look forward to receiving your contributions.

### Guest Editors

Dr. Elaine Dunlop

Division of Cancer and Genetics, Cardiff University, Cardiff, UK

Dr. Harilaos Filippakis

Department of Biomedical Sciences, College of Osteopathic Medicine, University of New England, Biddeford, ME, USA

### Deadline for manuscript submissions

closed (15 February 2024)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/si/130983](https://mdpi.com/si/130983)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)